Corporate Corruption Media Articles

Excerpts of Key Corporate Corruption Media Articles in Major Media

Below are key excerpts of revealing news articles on corporate corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

Secret emails reveal that the UK's biggest drug company distorted trial results of an anti-depressant, covering up a link with suicide in teenagers. GlaxoSmithKline (GSK) attempted to show that Seroxat worked for depressed children despite failed clinical trials. And that GSK-employed ghostwriters influenced 'independent' academics. GSK faces action in the US where bereaved families have joined together to sue the company. As a result, GSK has been forced to open its confidential internal archive. Karen Barth Menzies is a partner in one of the firms representing many of the families. She has examined thousands of the documents which are stored, box upon box, in an apartment in Malibu, California. She said: "Even when they have negative studies that show that this drug Seroxat is going to harm some kids they still spin that study as remarkably effective and safe for children." An email from a public relations executive working for GSK ... said: "Originally we had planned to do extensive media relations surrounding this study until we actually viewed the results. Essentially the study did not really show it was effective in treating adolescent depression, which is not something we want to publicise." Seroxat was banned for under 18s in 2003 after the MHRA revealed that GSK's own studies showed the drug actually trebles the risk of suicidal thoughts and behaviour in depressed children.

Note: For more reliable information on how the drug companies put profits ahead of your health, click here.

There are no magic bullets in the fight against cancer: that's the first thing every responsible scientist mentions when discussing a possible new treatment, no matter how promising. If there were a magic bullet, though, it might be something like dichloroacetate, or DCA, a drug that kills cancer cells by exploiting a fundamental weakness found in a wide range of solid tumors. So far, though, it kills them just in test tubes and in rats infected with human cancer cells; it has never been tested against cancer in living human beings. DCA ... is an existing drug whose side effects are well-studied and relatively tolerable. Also, it's a small molecule that might be able to cross the blood-brain barrier to reach otherwise intractable brain tumors. Within days after a technical paper on DCA appeared in the journal Cancer Cell last week, the lead author, Dr. Evangelos Michelakis of the University of Alberta, was deluged with calls and e-mails from prospective patients—to whom he can say only, “Hang in there.” DCA is a remarkably simple molecule. It acts in the body to promote the activity of the mitochondria. Researchers have assumed that the mitochondria in cancer cells were irreparably damaged. But Michelakis wondered if that was really true. With his colleagues he used DCA to turn back on the mitochondria in cancer cells—which promptly died. One of the great things about DCA is that it's a simple compound, in the public domain, and could be produced for pennies a dose. But that's also a problem, because big drug companies are unlikely to spend a billion dollars or so on large-scale clinical trials for a compound they can't patent.

Note: Read a 2010 follow-up by Dr. Michelakis with promising results and watch a 10-minute video. Explore the DCA website. Why didn't other mass media report this major story? Why aren't many millions of dollars being poured into research? Notice even Newsweek acknowledges the drug companies are not interested in finding a cure for cancer if they can't make a profit from it. Some suspect the drug companies have even suppressed cancer cures found in the past. See one amazing example of this. For more, see these major media articles on potential cancer cures.

The two sides in the debate over genetically modified crops issued warring reports assessing the first decade of the technology this week, as the industry's sunny view clashed with the darker vision of critics. The world's farmland planted with biotechnology crops reached 252 million acres in 2006, the industry-backed International Service for the Acquisition of Agri-Biotech Applications calculated in a report ... that promotes the products as solutions for hunger and future fuel demand. The report concluded that biotechnology boosts crop yields and benefits the environment. That view was challenged by Friends of the Earth International and the Center for Food Safety in a report released Wednesday. The two groups argued that engineered plants don't produce larger harvests than conventional varieties, are often more vulnerable to drought and have increased the use of pesticides. The United States and Argentina host about 70 percent of the world's biotech crop acreage, both sides said. But adoption of the technology is growing at a faster rate in developing countries than in industrialized nations, according to the International Service. About 10 million farmers in 22 countries sow genetically modified crops, it said. The dominant biotech crop is soybeans, with 57 percent of world acreage, followed by maize, cotton and canola. Opponents said the crops are mainly a boon to agribusiness and big agricultural chemical companies trying to increase sales of seeds, weed-killers and bug sprays. Biotech crop seeds are often engineered to be resistant to the herbicides or pesticides sold by the same company.

Note: For reliable information showing that you may be eating genetically modified food every day which scientific experiments have repeatedly demonstrated can cause sickness and even death, click here.

Data supplied by tobacco companies strongly suggest that in recent years manufacturers deliberately boosted nicotine levels in cigarettes to more effectively hook smokers, Harvard researchers conclude in a study being released today. The companies increasingly used tobacco richer in nicotine and made design changes to give smokers more puffs per cigarette, according to the analysis from the Harvard School of Public Health. The report expands on a landmark Massachusetts Department of Public Health study issued last August showing that the amount of nicotine that could be inhaled from cigarettes increased an average of 10 percent from 1998 through 2004. A 1996 state law required cigarette makers to test the nicotine that could be inhaled from their products, and the state ordered the use of machines that simulate a typical smoker's puffing. The Harvard researchers, who corroborated the basic findings of the state study, wanted to determine why cigarettes were delivering more nicotine. "Industry says it's changed," said Greg Connolly, an author of the Harvard study. "They've changed -- maybe for the worse." The Harvard study relies on information supplied by the industry. "It was systematic, it was pervasive, it involved all the manufacturers, and it was by design," said Dr. Howard Koh, an associate dean at the Harvard School of Public Health and an author of the study. Another author said that the likelihood that the nicotine increase happened by chance was less than 1 in 1,000.

In results that "astounded" scientists, an inexpensive molecule known as DCA was shown to shrink lung, breast and brain tumours in both animal and human tissue experiments. The study was published yesterday in the journal Cancer Cell. "I think DCA can be selective for cancer because it attacks a fundamental process of cancer that is unique to cancer cells," said Dr. Evangelos Michelakis, a professor at the Edmonton university's medical school and one of the study's key authors. The molecule appears to repair damaged mitochondria in cancer cells. "When a cell is getting too old or doesn't function properly, the mitochondria are going to induce the cell death," lead study author Sebastien Bonnet said yesterday. Bonnet says DCA – or dichloroacetate – appears to reverse the mitochondrial changes in a wide range of cancers. "One of the really exciting things about this compound is that it might be able to treat many different forms of cancer because all forms of cancer suppress mitochondrial function," Michelakis said. Bonnet says DCA may also provide an effective cancer treatment because its small size allows easy absorption into the body, ensuring it can reach areas that other drugs cannot, such as brain tumours. Because it's been used to combat other ailments ... DCA has been shown to have few toxic effects on the body. Its previous use means it can be immediately tested on humans. Unlike other cancer drugs, DCA did not appear to have any negative effect on normal cells. It could provide an extremely inexpensive cancer therapy because it's not patented. But ... the lack of a patent could lead to an unwillingness on the part of pharmaceutical companies to fund expensive clinical trials.

Note: Even these scientists realize that though this discovery could be a huge benefit to mankind, because the drug companies will lose profits, they almost certainly will not fund studies. Expensive AIDS drugs with promising results, on the other hand, are rushed through the studies to market. For more reliable, verifiable information on how hugely beneficial health advances are shut down to keep profits high, click here and here.

In the late spring of 1933, concentration camps such as Dachau were generating headlines reporting great brutality. Nonetheless, GM and Germany began a strategic business relationship. General Motors World, the company house organ, covered [a 1934] May Day event glowingly in a several-page cover story, stressing Hitler's boundless affinity for children. The next day, May 2, 1934, after practicing his sieg heil in front of a mirror, [President of GM Overseas Corp. James] Mooney ... went to meet Hitler. As Mooney traversed the long approach to Hitler's desk, he began to pump his arm in a stern-faced sieg heil. This was ... one of many contacts between the Nazis and GM officials that are spotlighted in thousands of pages of little-known and restricted Nazi-era and New Deal-era documents. The biggest automotive manufacturer in Germany -- indeed in all of Europe -- was General Motors, which since 1929 had owned and operated the longtime German company Opel. A few weeks after the [Hitler meeting], General Motors World effusively recounted ... "Hitler is a strong man, well fitted to lead the German people. He is leading them, not by force or fear, but by intelligent planning." In 1937, almost 17 percent of Opel's Blitz trucks were sold directly to the Nazi military. That military sales figure was increased to 29 percent in 1938. In 1938, just months after the Nazi annexation of Austria, Mooney, head of GM's overseas operations, received the German Eagle with Cross, the highest medal Hitler awarded to foreign commercial collaborators and supporters.

ExxonMobil Corp. gave $16 million to 43 ideological groups between 1998 and 2005 in an effort to mislead the public by discrediting the science behind global warming, the Union of Concerned Scientists asserted yesterday. The report by the advocacy group mirrors similar claims by Britain's leading scientific academy. Last September, The Royal Society wrote the oil company asking it to halt support for groups that "misrepresented the science of climate change." Alden Meyer, the Union of Concerned Scientists' strategy and policy director, said in a teleconference that ExxonMobil based its tactics on those of tobacco companies, spreading uncertainty by misrepresenting peer-reviewed scientific studies or emphasizing only selected facts. James McCarthy, a professor at Harvard University, said the company has sought to "create the illusion of a vigorous debate" about global warming.

Two UK-based academics have devised a way to invent new medicines and get them to market at a fraction of the cost charged by big drug companies. Sunil Shaunak, professor of infectious diseases at Imperial College ... calls their revolutionary new model "ethical pharmaceuticals". Improvements they devise to the molecular structure of an existing, expensive drug turn it technically into a new medicine which is no longer under a 20-year patent to a multinational drug company and can be made and sold cheaply. The process has the potential to undermine the monopoly of the big drug companies and bring cheaper drugs not only to poor countries but back to the UK. Professor Shaunak and his colleague from the London School of Pharmacy, Steve Brocchini, have linked up with an Indian biotech company which will manufacture the first drug - for hepatitis C. Hepatitis C affects 170 million people worldwide and at least 200,000 in the UK. Multinational drug companies put the cost of the research and development of a new drug at $800m (Ł408m). Professors Shaunak and Brocchini say the cost of theirs will be only a few million pounds. Professor Shaunak says it is time that the monopoly on drug invention and production by multinational corporations - which charge high prices because they need to make big profits for their shareholders - was broken. The team's work on the hepatitis C drug has impeccable establishment credentials. But the professors' ethical pharmaceutical model is unlikely to find much favour with the multinational pharmaceutical companies, which already employ large teams of lawyers to defend the patents which they describe as the lifeblood of the industry.

Note: This is very exciting news, but we'll see what happens when the hugely profitable pharmaceutical industry presses its might against this effort. For more, click here.

The drug maker Eli Lilly has engaged in a decade-long effort to play down the health risks of Zyprexa, its best-selling medication for schizophrenia, according to hundreds of internal Lilly documents and e-mail messages among top company managers. The documents ... show that Lilly executives kept important information from doctors about Zyprexa’s links to obesity and its tendency to raise blood sugar — both known risk factors for diabetes. Lilly’s own published data, which it told its sales representatives to play down in conversations with doctors, has shown that 30 percent of patients taking Zyprexa gain 22 pounds or more after a year on the drug, and some patients have reported gaining 100 pounds or more. But Lilly was concerned that Zyprexa’s sales would be hurt if the company was more forthright about the fact that the drug might cause unmanageable weight gain or diabetes, according to the documents, which cover the period 1995 to 2004. Zyprexa has become by far Lilly’s best-selling product, with sales of $4.2 billion last year, when about two million people worldwide took the drug. Critics, including the American Diabetes Association, have argued that Zyprexa, introduced in 1996, is more likely to cause diabetes than other widely used schizophrenia drugs. As early as 1999, the documents show that Lilly worried that side effects from Zyprexa, whose chemical name is olanzapine, would hurt sales. “Olanzapine-associated weight gain and possible hyperglycemia is a major threat to the long-term success of this critically important molecule,” Dr. Alan Breier wrote in a November 1999 e-mail message to two-dozen Lilly employees.

Note: For lots more on corporate corruption from reliable sources, click here.

One hundred years ago, companies were free to follow their own rules. The publication of Upton Sinclair’s novel “The Jungle” in 1906 — with its descriptions of rat-infested slaughterhouses and rancid meat — created public outrage over food safety. Even though the book was written by a socialist agitator, a Republican president, Theodore Roosevelt, eagerly read it. After confirming Sinclair’s claims, Roosevelt battled the drug companies, the big food processors and the meatpacking companies to protect American consumers from irresponsible corporate behavior. Over the past 40 years, the industrialization and centralization of our food system has greatly magnified the potential for big outbreaks. As a result, a little contamination can go a long way. The Taco Bell distribution center in New Jersey now being investigated as a possible source of E. coli supplies more than 1,100 restaurants in the Northeast. Since 2000, the fast-food and meatpacking industries have given about four-fifths of their political donations to Republican candidates for national office. In return, these industries have effectively been given control of the agencies created to regulate them. The current chief of staff at the Agriculture Department used to be the beef industry’s chief lobbyist. The person who headed the Food and Drug Administration until recently used to be an executive at the National Food Processors Association. Cutbacks in staff and budgets have reduced the number of food-safety inspections conducted by the F.D.A. to about 3,400 a year — from 35,000 in the 1970s.

Note: If you care about the health of our nation's food supply, write your political and media representatives encouraging the passage of the Safe Food Act mentioned in this article, which by the way, was written by the author of the most excellent book, Fast Food America.

While the Bush administration, the media and nearly all the Democrats still refuse to explain the war in Iraq in terms of oil, the ever-pragmatic members of the Iraq Study Group share no such reticence. Page 1, Chapter 1 ... lays out Iraq's importance: "It has the world's second-largest known oil reserves." The report makes visible to everyone the elephant in the room: that we are fighting, killing and dying in a war for oil. Recommendation No. 63 ... calls on the U.S. to "assist Iraqi leaders to reorganize the national oil industry as a commercial enterprise." This is an echo of calls made [by] the U.S. State Department's Oil and Energy Working Group, meeting between December 2002 and April 2003. Iraq "should be opened to international oil companies as quickly as possible after the war." Its preferred method of privatization was a form of oil contract called a production-sharing agreement. These agreements are ... rejected by all the top oil producers in the Middle East because they grant greater control and more profits to the companies than the governments. For any degree of oil privatization to take place ... Iraq has to amend its constitution. Recommendation No. 26 of the Iraq Study Group calls for a review of the constitution to be "pursued on an urgent basis." Petroleum Economist magazine later reported that U.S. oil companies considered passage of the new oil law more important than increased security. Further, the Iraq Study Group would commit U.S. troops to Iraq for several more years to ... provide security for Iraq's oil infrastructure. We can thank the Iraq Study Group for making its case publicly. It is now our turn to decide if we wish to spill more blood for oil.

Note: For more on corporate complicity in fomenting war exposed by a top U.S. general, click here.

The scientist who first linked smoking to lung cancer was [later] paid by a chemicals firm while investigating cancer risks in the industry. Professor Sir Richard Doll held a consultancy post with US firm Monsanto for more than 20 years. The BBC has seen private letters which show that Sir Richard ... received a US$1,500-a-day consultancy fee from Monsanto in the mid-1980s. During that time he investigated the potential cancer causing properties of the powerful herbicide Agent Orange, made by the company. Sir Richard [argued] that there was no evidence that Agent Orange caused cancer. Professor Lennart Hardell, of the Oncology Department at University Hospital Orebro, Sweden, has also studied the potential hazards posed by Agent Orange. He was one of the scientists whose work was dismissed by Sir Richard. He said: "It's quite OK to have contacts with industry, but you should be fair and say 'well, I'm [working] as a consultant for Monsanto." Further documents obtained by The Guardian newspaper allegedly show that Sir Richard was also paid a Ł15,000 fee by the Chemical Manufacturers Association, and chemicals companies Dow Chemicals and ICI for a review of vinyl chloride, used in plastics, which largely cleared the chemical of any link with cancers apart from liver cancer. Sir Richard's views on the chemical were used by the manufacturers' trade association to defend it for more than a decade.

During a 22-year career, Bobby L. Maxwell routinely won accolades and awards as one of the Interior Department’s best auditors in the nation’s oil patch. “Mr. Maxwell’s career has been characterized by exceptional performance and significant contributions,” wrote Gale A. Norton, then the secretary of the interior, in a 2003 citation. Less than two years later, the Interior Department eliminated his job. That came exactly one week after a federal judge in Denver unsealed a lawsuit in which Mr. Maxwell contended that a major oil company had spent years cheating on royalty payments. Invoking a law that rewards private citizens who expose fraud against the government, Mr. Maxwell has filed a suit [which] contends that the Interior Department ignored audits indicating that Kerr-McGee was cheating. Maxwell says his first serious doubts about the Interior Department originated in 1998, when the agency reluctantly began to investigate accusations of systematic cheating on royalties for oil. Several of the nation’s biggest oil companies eventually settled that investigation by paying nearly $440 million. Mr. Maxwell said, “There have always been people who don’t want to pursue things. But now it’s grown into a major illness.” Broader investigations by Congress and the Interior Department’s own inspector general [are investigating] whether the agency properly collects the money for oil and gas pumped from public land. The Interior Department’s inspector general told a House subcommittee in September that senior officials at the agency had repeatedly glossed over ethical lapses. “Short of crime, anything goes at the highest levels of the Department of the Interior,” declared Earl E. Devaney, the inspector general.

Note: If you want to understand how corruption can grow and fester in large government agencies, this entire article is highly educational and revealing.

After six years of technological research, more than $4 billion spent by Washington on new machinery and a widespread overhaul of the nation’s voting system, this month’s midterm election revealed that the country is still far from able to ensure that every vote counts. Tens of thousands of voters, scattered across more than 25 states, encountered serious problems at the polls. The difficulties led to shortages of substitute paper ballots and long lines that caused many voters to leave without casting ballots. Voting experts say it is impossible to say how many votes were not counted that should have been. In Florida alone, the discrepancies ... amount to more than 60,000 votes. In Colorado, as many as 20,000 people gave up trying to vote ... as new online systems for verifying voter registrations crashed repeatedly. In Arkansas, election officials tallied votes three times in one county, and each time the number of ballots cast changed by more than 30,000. Election experts say that with electronic voting machines, the potential consequences of misdeeds or errors are of a [great] magnitude. A single software error can affect thousands of votes, especially with machines that keep no paper record. In Ohio, thousands of voters were turned away or forced to file provisional ballots by poll workers puzzled by voter-identification rules. In Pennsylvania, the machines crashed or refused to start, producing many reports of vote-flipping [where] voters press the button for one candidate but a different candidate’s name appears on the screen. In Ohio, even a congressman, Steve Chabot, a Republican, was turned away from his polling place because the address listed on his driver’s license was different than his home address.

An Associated Press analysis suggests that big oil companies have been crimping supplies ... across the country for years. The analysis, based on data from the U.S. Energy Information Administration, indicates that the industry slacked off supplying oil and gasoline during the prolonged price boom between early 1999 and last summer, when prices began to fall. The findings support a conclusion already reached by many motorists. Fifty-five percent of Americans believe gas prices are high because [of] oil companies. Though set back temporarily by the [9/11] attacks, the oil business has profited handsomely since then. The biggest six refiners ... rang up $400 billion in profits since 2001. Though reserves have kept pretty steady, the oil industry taps those resources to varying degrees from year to year. The industry has shelved an average of 21 percent more unrefined oil from the start of 2004 through last June. Last spring, stocks of shelved crude reached their highest level in eight years, despite the fabulous riches at hand in high prices then. The industry also protected profits by not building any new refineries. [And] thanks to mergers, the top 10 companies now control three-quarters of national refining capacity, up from half in the early 1990s. A 2001 study by the Federal Trade Commission reported that some firms were deciding to "maximize their profits" by crimping supply. One executive told regulators "he would rather sell less gasoline and earn a higher margin on each gallon sold." However upsetting to drivers, such tactics are usually viewed as legal. "A decision to limit supply does not violate the antitrust laws," regulators wrote in one FTC report.

At hundreds of screenings this year of "An Inconvenient Truth," the first thing many viewers said after the lights came up was that every student in every school in the United States needed to see this movie. The producers of former vice president Al Gore's film about global warming ... certainly agreed. So the company that made the documentary decided to offer 50,000 free DVDs to the National Science Teachers Association (NSTA). It seemed like a no-brainer. In their e-mail rejection, they expressed concern that ... they didn't want to offer "political" endorsement of the film; and they saw "little, if any, benefit to NSTA or its members" in accepting the free DVDs. As for classroom benefits, the movie has been enthusiastically endorsed by leading climate scientists worldwide, and is required viewing for all students in Norway and Sweden. But there was one more curious argument in the e-mail: Accepting the DVDs, they wrote, would place "unnecessary risk upon the [NSTA] capital campaign, especially certain targeted supporters." One of those supporters, it turns out, is the Exxon Mobil Corp. That's the same Exxon Mobil that for more than a decade has done everything possible to muddle public understanding of global warming and stifle any serious effort to solve it. It has run ads in leading newspapers ... questioning the role of manmade emissions in global warming, and financed the work of a small band of scientific skeptics who have tried to challenge the consensus that heat-trapping pollution is drastically altering our atmosphere. NSTA says it has received $6 million from the company since 1996. Exxon Mobil has a representative on the group's corporate advisory board.

Hoping to prevent Congress from letting the government negotiate lower drug prices for millions of older Americans on Medicare, the pharmaceutical companies have been recruiting Democratic lobbyists [and] lining up allies in the Bush administration and Congress. Many drug company lobbyists concede that the House is likely to pass a bill intended to drive down drug prices, but they are determined to block such legislation in the Senate. If that strategy fails, they are counting on President Bush to veto any bill that passes. With 49 Republicans in the Senate next year, the industry is confident that it can round up the 34 votes normally needed to uphold a veto. They began developing strategy last week at a meeting of the board of the Pharmaceutical Research and Manufacturers of America. Billy Tauzin, president of that group [and] a former congressman...met with Senator Byron L. Dorgan, a North Dakota Democrat who has been trying for six years to allow drug imports from Canada. The industry vehemently opposes such legislation. The 2003 Medicare law prohibits the federal government from negotiating drug prices or establishing a list of preferred drugs. Drug makers have not set a budget for their campaign. They and their trade groups already spend some $100 million a year on lobbying in Washington. Representative Frank Pallone Jr., Democrat of New Jersey [said] “The 2003 Medicare law was essentially written by the drug industry.” Drug companies may be open to some changes in the Medicare drug benefit, but they say they cannot accept any form of price negotiation.

Note: For lots of verifiable information on the power of the drug industry to corrupt Congress, click here.

The most important--and unfortunately the least debated--issue in politics today is our society's steady drift toward a class-based system, the likes of which we have not seen since the 19th century. America's top tier has grown infinitely richer and more removed over the past 25 years. Few among them send their children to public schools; fewer still send their loved ones to fight our wars. They own most of our stocks, making the stock market an unreliable indicator of the economic health of working people. The top 1% now takes in an astounding 16% of national income, up from 8% in 1980. The tax codes protect them, just as they protect corporate America, through a vast system of loopholes. Incestuous corporate boards regularly approve compensation packages for chief executives and others that are out of logic's range. As this newspaper has reported, the average CEO of a sizeable corporation makes more than $10 million a year, while the minimum wage for workers amounts to about $10,000 a year, and has not been raised in nearly a decade. When I graduated from college in the 1960s, the average CEO made 20 times what the average worker made. Today, that CEO makes 400 times as much. Trickle-down economics didn't happen. Wages and salaries are at all-time lows as a percentage of the national wealth. This ever-widening divide is too often ignored or downplayed by its beneficiaries. A sense of entitlement has set in among elites, bordering on hubris.

Note: For some reason the Wall Street Journal has removed this article. You can read it on the website of the article's author at this link.

Investigations led by a Republican lawyer named Stuart W. Bowen Jr. in Iraq have sent American occupation officials to jail on bribery and conspiracy charges, exposed disastrously poor construction work by well-connected companies like Halliburton and Parsons, and discovered that the military did not properly track hundreds of thousands of weapons it shipped to Iraqi security forces. And tucked away in a huge military authorization bill that President Bush signed two weeks ago is what some of Mr. Bowen’s supporters believe is his reward for repeatedly embarrassing the administration: a pink slip. An obscure provision...terminates his federal oversight agency, the Office of the Special Inspector General for Iraq Reconstruction. The clause was inserted by the Republican side of the House Armed Services Committee. It has generated surprise and some outrage among lawmakers who say they had no idea it was in the final legislation. Susan Collins, a Maine Republican who followed the bill closely as chairwoman of the Senate Committee on Homeland Security and Government Affairs, says that she still does not know how the provision made its way into what is called the conference report, which reconciles differences between House and Senate versions of a bill. Neither the House nor the Senate version contained such a termination clause before the conference, all involved agree. Mr. Bowen’s office has 55 auditors and inspectors in Iraq and about 300 reports and investigations already to its credit, far outstripping any other oversight agency in the country.

Diebold Inc. demanded that cable network HBO cancel a documentary that questions the integrity of its voting machines, calling the program inaccurate and unfair. The program, "Hacking Democracy," is scheduled to debut on Nov. 2, five days before the 2006 U.S. midterm elections. The film claims Diebold voting machines aren't tamper-proof and can be manipulated to change voting results. "Hacking Democracy" is "replete with material examples of inaccurate reporting," Diebold Election System President David Byrd said in a letter to HBO President and Chief Executive Officer Chris Albrecht. "We stand by the film," HBO spokesman Jeff Cusson said in an interview. "We have no intention of withdrawing it from our schedule." This is Diebold's second defense of its system since last month. On Sept. 26, Byrd wrote to Jann Wenner, editor and publisher of Rolling Stone, saying a story written by Robert F. Kennedy Jr., "Will the Next Election Be Hacked?" was "error- riddled" and that readers "deserve a better researched and reported article." The documentary is based on the work of Bev Harris of Renton, founder of BlackBoxVoting.org, which monitors election accuracy. Harris says on the HBO Web site that she found "secret program files" used by Diebold for its electronic voting machines. Harris copied them and distributed the programs to others as a way to show the vulnerability of a system designed to safeguard voting, according to the Web site.

Note: For the revealing story in Rolling Stone, click here.

Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.